Use of MDMA and Other Illicit Drugs by Young Adult Males in Northern Spain
Julio Bobes, Pilar A. Sáiz, María Paz García‐portilla, Teresa Bascarán, Manuel Bousoño, George A. Ricaurte, U. Mccann
European Addiction Research 2002 DOI: 10.1159/000059385 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 3,634 |
| Population | Young males entering compulsory military service in Asturias, Spain |
| Topics | Cannabis MDMA |
| Keywords | Psychoticism Sensation seeking Neuroticism Hallucinogen Eysenck personality questionnaire Hashish Clinical psychology Substance abuse Demography |
| Citations | 34 |
| Key findings | MDMA users had higher scores on Neuroticism and Psychoticism and higher sensation seeking compared to non-users. |
Abstract
Aim: To measure the prevalence of 3,4-methylenedioxymethamphetamine (MDMA) and other drug use in young males entering compulsory military service in Asturias (northern Spain) and to define trends in MDMA use in this group during the period from 1995 to 1999. We also sought to determine whether MDMA users have distinct personality features or higher levels of sensation seeking.
Methods: 3,634 conscripts [mean age (SD) = 20.19 years (2.52)] who entered military service during the period between 1995 and 1999 were evaluated using the World Health Organization (WHO) questionnaire for drug consumption, the Eysenck Personality Questionnaire-A (EPQ-A), and the Zuckerman Sensation Seeking Scale. Results and
Conclusions: The prevalence of lifetime, previous year and previous month MDMA use among military recruits between 1995 and 1999 was 10.9, 7.8 and 4.5%, ranking fifth among illicit drugs ever used. Once individuals used MDMA for the first time, they were likely to use it again, with 71% of individuals who had ever used MDMA reporting that they had used it during the past year (ranking second only to hallucinogens), and 41% reporting having used it in the last month. Compared to recruits who had never used MDMA (but who may have used other illicit drugs), MDMA users had a more extensive drug abuse history. Recruits who had used MDMA during the year prior to study had significantly higher scores on the Neuroticism and Psychoticism Subscales of the EPQ-A, and reported higher levels of sensation seeking.
Comparable studies
Other observational and cohort studies on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Subjective Reports of the Effects of MDMA in a Clinical Setting Individuals who took MDMA in a clinical setting | 1986 | Observational study | |
| Memory impairment in abstinent MDMA ("Ecstasy") users Abstinent MDMA users | 1998 | Observational cohort | |
| Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people | 2000 | Observational | |
| The Psychological and Physiological Effects of MDMA on Normal Volunteers Older, more educated, drug-experienced individuals | 1986 | Observational cohort | |
| Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits Young people who were regular or novice MDMA users, or non-users | 1998 | Observational cohort | n = 30 |
Citations in the library
Cited by 3
- 3,4-Methylenedioxymethamphetamine (MDMA) Intoxication in an Infant Chronically Exposed to Cocaine Therapeutic Drug Monitoring July 22, 2005
- Neurochemical substrates of the rewarding effects of MDMA: implications for the development of pharmacotherapies to MDMA dependence. Behavioural Pharmacology April 2016
- The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine. Basic & Clinical Pharmacology & Toxicology January 2008
Cites 5
- Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings The Lancet October 1, 1998
- 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Journal of Pharmacology and Experimental Therapeutics September 1, 1987
- Reducedin vivobinding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users The British Journal of Psychiatry July 1, 1999
- Serotonergic function after (±)3,4-methylene-dioxymethamphetarnine (‘Ecstasy’) in humans International Clinical Psychopharmacology 1998
- 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Research December 6, 1988